The dual Hcrt receptor antagonist suvorexant has been shown to be effective as a treatment for insomnia in clinical trials (Herring et al., 2014; Winrow and Renger, 2014), providing a new path for understanding the natural history of insomnia and the role of the hypocretin system in this disorder. The gene discussed is HCRT; the disease is insomnia measurement.